Sandbox Reserved 162
From Proteopedia
| Line 3: | Line 3: | ||
__TOC__ | __TOC__ | ||
== Background == | == Background == | ||
| - | Human Interleukin-6 (IL-6) is a immune protein often categorized under hematopoietins. Since its discoverey, it has been known by many names including: interferon-ß2 (IFN-ß2), 26-kD protein, B-cell stimulatory factor-2 (BSF-2), hepatocyte stimulating factor (HSF), cytotoxic T-cell differentiation factor (CDF), interleukin-HP1 (IL-HP1), monocyte-granulocyte inducer type 2 (MGI-2), and hybridoma/plasmacytoma growth factor (HPGF/HGF). It wasn't until December of 1988 that is was givin the final moniker of IL-6 (PDB: 1IL6) | + | Human Interleukin-6 (IL-6) is a immune protein often categorized under hematopoietins. Since its discoverey, it has been known by many names including: interferon-ß2 (IFN-ß2), 26-kD protein, B-cell stimulatory factor-2 (BSF-2), hepatocyte stimulating factor (HSF), cytotoxic T-cell differentiation factor (CDF), interleukin-HP1 (IL-HP1), monocyte-granulocyte inducer type 2 (MGI-2), and hybridoma/plasmacytoma growth factor (HPGF/HGF). It wasn't until December of 1988 that is was givin the final moniker of IL-6 (PDB: 1IL6). The protein encoded by this gene is a subunit of the receptor complex for IL6. |
== Structure == | == Structure == | ||
| Line 10: | Line 10: | ||
== Functions == | == Functions == | ||
| + | Interleukin 6 (IL6) is a potent polyfunctional cytokine that plays a vital role in host defense. This is demonstrated by its potent ability to induce acute-phase responses in the liver. | ||
== IL-6 Receptor == | == IL-6 Receptor == | ||
| Line 15: | Line 16: | ||
== Clinical Applications == | == Clinical Applications == | ||
| - | Dysregulated production of IL6 and this receptor are implicated in the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases and prostate cancer. Alternatively spliced transcript variants encoding distinct isoforms have been reported. | + | Dysregulated production of IL6 and this receptor are implicated in the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases and prostate cancer. Alternatively spliced transcript variants encoding distinct isoforms have been reported. |
| + | A good correlation has been found between levels of IL-6 and bone loss in patients with Paget's disease and multiple myeloma. In those patients, higher levels of IL-6 correlated to higher rates of bone loss. Additionally, IL-6 levels decreased with increasing levels of estrogen. These findings strongly suggest that IL-6 plays a key roll in post-menopausal bone loss. | ||
== Additional Resources == | == Additional Resources == | ||
Revision as of 18:48, 26 March 2011
|
Contents |
Background
Human Interleukin-6 (IL-6) is a immune protein often categorized under hematopoietins. Since its discoverey, it has been known by many names including: interferon-ß2 (IFN-ß2), 26-kD protein, B-cell stimulatory factor-2 (BSF-2), hepatocyte stimulating factor (HSF), cytotoxic T-cell differentiation factor (CDF), interleukin-HP1 (IL-HP1), monocyte-granulocyte inducer type 2 (MGI-2), and hybridoma/plasmacytoma growth factor (HPGF/HGF). It wasn't until December of 1988 that is was givin the final moniker of IL-6 (PDB: 1IL6). The protein encoded by this gene is a subunit of the receptor complex for IL6.
Structure
IL-6 is a monomer of 185 amino acids produced from T-Cells, macrophages, and endothelial cells found on a single gene at locus 7p21. It contains five alpha-helices and four of these helices constitute a classical four-helix bundle with the fifth helix located in the CD loop.
Functions
Interleukin 6 (IL6) is a potent polyfunctional cytokine that plays a vital role in host defense. This is demonstrated by its potent ability to induce acute-phase responses in the liver.
IL-6 Receptor
|
Clinical Applications
Dysregulated production of IL6 and this receptor are implicated in the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases and prostate cancer. Alternatively spliced transcript variants encoding distinct isoforms have been reported. A good correlation has been found between levels of IL-6 and bone loss in patients with Paget's disease and multiple myeloma. In those patients, higher levels of IL-6 correlated to higher rates of bone loss. Additionally, IL-6 levels decreased with increasing levels of estrogen. These findings strongly suggest that IL-6 plays a key roll in post-menopausal bone loss.
